Praxis Precision Medicines, Inc. Announces Proposed Public Offering
BOSTON, Jan. 10, 2024 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock. All securities in the offering will be offered by Praxis. In addition, Praxis intends to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount up to 15% of the shares of common stock (or prefunded warrants in lieu thereof) sold in the offering at the public offering price, less the underwriting discount and commission.
Related news for (PRAX)
- Power Hour Pulse: From Helium Hype to Quantum Defense — Stocks to Watch into the Close
- Morning Movers & Moonshots: VirnetX Rockets, Carbon Revolution Accelerates, and Disc Medicine Grabs FDA’s Fast Track
- Biotech Breakouts, Amphitheater Ambitions, and Chips on the Move
- PRAXIS RISES, VENU VIBES, AND J.B. HUNT DELIVERS
- Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event